Carcinoid syndrome is a collection of symptoms caused by neuroendocrine tumors that release excess serotonin and other hormones into the bloodstream. It most commonly develops when a neuroendocrine tumor in the small intestine has spread to the liver, allowing those hormones to bypass the liver’s normal filtering process and circulate throughout the body. The hallmark symptoms are skin flushing and persistent diarrhea, though the syndrome can also affect the heart and lungs.
Why It Happens
Neuroendocrine tumors produce roughly 40 different biologically active substances, but serotonin is the one most responsible for carcinoid syndrome. Normally, when a tumor sits in the gut, the hormones it releases drain through the portal vein into the liver, which breaks them down before they ever reach the rest of the body. That built-in filter is why most people with neuroendocrine tumors never develop the syndrome at all.
The situation changes when tumor cells spread to the liver itself. Metastatic deposits in the liver dump hormones directly into the hepatic veins, which feed straight into systemic circulation. From there, serotonin and related compounds act on blood vessels, the gut lining, heart valves, and airways. In rare cases, tumors outside the gut’s drainage system, such as those in the lungs or ovaries, can trigger the syndrome without liver metastases because their hormones never pass through the liver in the first place.
How Common Are Neuroendocrine Tumors
Neuroendocrine tumors are uncommon but increasingly diagnosed. The age-adjusted incidence in the United States climbed more than fivefold between 1975 and 2021, from about 1.6 to 8.5 cases per 100,000 people per year. Much of that increase reflects better imaging and more routine biopsies rather than a true surge in disease. The most frequent primary sites are the gastrointestinal and pancreatic region (about 6.1 per 100,000) and the lung (about 1.5 per 100,000). Within the GI tract, the small bowel and pancreas are the most common origins.
Only a subset of people with neuroendocrine tumors develop carcinoid syndrome. The syndrome is primarily associated with midgut tumors, meaning those in the distal small intestine and the first part of the colon, and it almost always signals that the cancer has already metastasized.
Symptoms
Flushing is the most common symptom, reported in about 85% of patients. Episodes typically involve a sudden reddening of the face and upper body that can last anywhere from 30 seconds to 30 minutes. They may happen spontaneously or be triggered by eating, drinking alcohol, emotional stress, or physical exertion. The flushing itself is caused by hormones acting on blood vessels near the skin’s surface.
Diarrhea affects roughly 80% of patients. It tends to be watery and frequent, driven by serotonin’s effect on gut motility. For many people, the diarrhea is the most disruptive day-to-day symptom, sometimes occurring many times a day regardless of diet.
Wheezing and shortness of breath occur in 10% to 20% of patients, often during flushing episodes. These bronchospasm episodes result from the same circulating hormones that cause flushing, but their target is the smooth muscle lining the airways.
Because neuroendocrine tumors divert tryptophan toward serotonin production, less tryptophan is available to make niacin (vitamin B3). Over time this can lead to niacin deficiency, which causes skin rashes, diarrhea, and in severe cases, cognitive changes. Fatigue is also common and often underappreciated.
Heart Valve Damage
Cardiac involvement is one of the more serious complications, occurring in up to 60% of patients with carcinoid syndrome. Serotonin and related substances cause fibrous tissue to build up on heart valves, particularly on the right side of the heart. The tricuspid valve (between the right atrium and right ventricle) is affected most often, with thickened, shortened leaflets that fail to close properly. Up to 80% of patients with carcinoid heart disease also develop problems with the pulmonary valve.
The reason the right side is disproportionately affected is anatomical: venous blood carrying excess serotonin hits the right heart first. The lungs then metabolize much of the serotonin before blood reaches the left side, which is why left-sided valve disease is rare in carcinoid syndrome. Over time, right-sided valve dysfunction leads to fluid retention, swelling in the legs, and progressive heart failure. Echocardiography is used to monitor for valve changes, and some patients eventually need valve replacement surgery.
How It Is Diagnosed
The primary diagnostic test measures a serotonin breakdown product called 5-HIAA in a 24-hour urine collection. Elevated levels above the upper reference limit (40 micromoles per 24 hours in most labs) confirm that the body is producing excess serotonin. The test has high specificity, around 95%, meaning a positive result is reliable.
Accurate results require some preparation. Certain foods rich in tryptophan, including bananas, pineapple, nuts, chocolate, coffee, and tea, can artificially raise 5-HIAA levels. Patients need to avoid these foods for three days before and during the urine collection. Some medications can also skew results in either direction.
Once elevated 5-HIAA confirms the syndrome, imaging is used to locate the primary tumor and any metastases. Specialized scans that detect somatostatin receptors on tumor cells are particularly useful for mapping the extent of disease and guiding treatment decisions.
First-Line Treatment
The backbone of symptom management is a class of medications called somatostatin analogs. These drugs mimic a natural hormone that inhibits the release of serotonin and other active substances from tumor cells. Two long-acting formulations are standard: one given as an intramuscular injection every four weeks and another as a deep subcutaneous injection on the same schedule. Both reduce flushing, diarrhea, and other hormone-driven symptoms in the majority of patients.
Beyond symptom relief, somatostatin analogs also slow tumor growth. International guidelines recommend them as first-line treatment for both symptom control and disease stabilization in advanced gastrointestinal and lung neuroendocrine tumors. For patients experiencing breakthrough symptoms between injections, short-acting versions can be administered multiple times daily as needed.
When First-Line Therapy Is Not Enough
If tumors progress despite somatostatin analogs, a targeted radiation treatment called peptide receptor radionuclide therapy (PRRT) is an established second-line option. PRRT works by attaching a radioactive molecule to a compound that binds to receptors on tumor cells, delivering radiation directly to the cancer while largely sparing healthy tissue.
In the landmark clinical trial comparing PRRT plus standard care to standard care alone in patients with progressive midgut neuroendocrine tumors, 65% of patients in the PRRT group were progression-free at 20 months compared to just 11% in the control group. Median overall survival was 48 months with PRRT versus 36 months without it. Across a large meta-analysis of over 1,700 patients, PRRT achieved disease control (meaning the tumor shrank or stayed stable) in about 80% of cases.
Candidates for PRRT need to have tumors that strongly express somatostatin receptors, confirmed by specialized imaging. It is generally recommended for patients with grade 1 or grade 2 tumors that are progressing, though select patients with higher-grade tumors may also qualify if their tumors show strong receptor uptake and their overall health allows it.
Carcinoid Crisis
Carcinoid crisis is a rare but potentially life-threatening emergency in which a massive surge of hormones floods the bloodstream all at once. It most often occurs during surgery, anesthesia, or other procedures that physically manipulate tumor tissue. Symptoms include a dangerous drop in blood pressure (below 80 mmHg for 10 or more minutes), rapid heart rate above 120 beats per minute, severe flushing, wheezing, and in extreme cases, heart rhythm disturbances.
Liver metastasis is the strongest risk factor, roughly tripling the odds of crisis during surgery. To prevent it, patients with known carcinoid syndrome receive preventive infusions of somatostatin analogs before, during, and after any surgical procedure. Additional doses are kept on hand in the operating room in case a crisis develops despite prophylaxis.
Living With Carcinoid Syndrome
Day-to-day management revolves around consistent medication, symptom tracking, and avoiding known triggers. Alcohol is one of the most reliable triggers for flushing episodes. Emotional stress, strenuous exercise, and large meals can also provoke symptoms in some people. Keeping a symptom diary helps identify personal patterns that may not be obvious at first.
Nutritional monitoring matters because the serotonin overproduction depletes tryptophan stores and can lead to niacin deficiency over time. Niacin supplementation is often recommended. Regular echocardiograms, typically every year or so, are important for catching valve changes before they cause significant heart failure. Because the syndrome almost always reflects metastatic disease, ongoing imaging to track tumor burden is part of long-term care as well.